These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 33848334)

  • 1. Sofosbuvir-based hepatitis C therapies in patients with chronic and end-stage kidney disease.
    Sise ME; McQuaid T; Martin P
    Nephrol Dial Transplant; 2022 Nov; 37(12):2327-2334. PubMed ID: 33848334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HEPATITIS C TREATMENT OF RENAL TRANSPLANT AND CHRONIC KIDNEY DISEASE PATIENTS: EFFICACY AND SAFETY OF DIRECT-ACTING ANTIVIRAL REGIMENS CONTAINING SOFOSBUVIR.
    Michels FBL; Amaral ACC; Carvalho-Filho RJ; Vieira GA; Souza ALDS; Ferraz MLG
    Arq Gastroenterol; 2020; 57(1):45-49. PubMed ID: 32294735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function.
    Shin HP; Park JA; Burman B; Kozarek RA; Siddique A
    Clin Mol Hepatol; 2017 Dec; 23(4):316-322. PubMed ID: 28827512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4-5 chronic kidney disease: a systematic review and meta-analysis.
    Li M; Chen J; Fang Z; Li Y; Lin Q
    Virol J; 2019 Mar; 16(1):34. PubMed ID: 30871566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sofosbuvir-based regimens for HCV in stage 4-stage 5 chronic kidney disease. A systematic review with meta-analysis.
    Fabrizi F; Cerutti R; Dixit V; Ridruejo E
    Nefrologia (Engl Ed); 2021; 41(5):578-589. PubMed ID: 36165141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis.
    Borgia SM; Dearden J; Yoshida EM; Shafran SD; Brown A; Ben-Ari Z; Cramp ME; Cooper C; Foxton M; Rodriguez CF; Esteban R; Hyland R; Lu S; Kirby BJ; Meng A; Markova S; Dvory-Sobol H; Osinusi AO; Bruck R; Ampuero J; Ryder SD; Agarwal K; Fox R; Shaw D; Haider S; Willems B; Lurie Y; Calleja JL; Gane EJ
    J Hepatol; 2019 Oct; 71(4):660-665. PubMed ID: 31195062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals.
    Liu CH; Lee MH; Lin JW; Liu CJ; Su TH; Tseng TC; Chen PJ; Chen DS; Kao JH
    J Hepatol; 2020 May; 72(5):839-846. PubMed ID: 31790766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
    García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F
    Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Information on Pan-Genotypic Direct-Acting Antiviral Agents for HCV in Chronic Kidney Disease.
    Fabrizi F; Tripodi F; Cerutti R; Nardelli L; Alfieri CM; Donato MF; Castellano G
    Viruses; 2022 Nov; 14(11):. PubMed ID: 36423179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute interstitial nephritis following treatment with direct-acting antiviral agents in hepatitis C virus-infected patients: A case series.
    Duque JC; Dejman A; Venkat V; Hernandez M; Roth D; Ladino MA
    Clin Nephrol; 2021 Jan; 95(1):22-27. PubMed ID: 32909545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure.
    Dumortier J; Bailly F; Pageaux GP; Vallet-Pichard A; Radenne S; Habersetzer F; Gagnieu MC; Grangé JD; Minello A; Guillaud O; Kamar N; Alric L; Leroy V
    Nephrol Dial Transplant; 2017 Dec; 32(12):2065-2071. PubMed ID: 27760839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sofosbuvir and risk of estimated glomerular filtration rate decline or end-stage renal disease in patients with renal impairment.
    Sulkowski M; Telep LE; Colombo M; Durand F; Reddy KR; Lawitz E; Bourlière M; Cheinquer N; Scherbakovsky S; Ni L; Force L; Ramroth H; Gaggar A; Chokkalingam AP; Sise ME
    Aliment Pharmacol Ther; 2022 May; 55(9):1169-1178. PubMed ID: 35235245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sofosbuvir plus velpatasvir combination for the treatment of chronic hepatitis C in patients with end stage renal disease on renal replacement therapy: A systematic review and meta-analysis.
    De A; Roy A; Verma N; Mishra S; Premkumar M; Taneja S; Singh V; Duseja A
    Nephrology (Carlton); 2022 Jan; 27(1):82-89. PubMed ID: 34453374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
    Manoj Kumar ; Nayak SL; Gupta E; Kataria A; Sarin SK
    Liver Int; 2018 Dec; 38(12):2137-2148. PubMed ID: 29676846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease.
    Ridruejo E; Garcia-Agudo R; Mendizabal M; Aoufi-Rabih S; Dixit V; Silva M; Fabrizi F
    Nefrologia (Engl Ed); 2020; 40(1):46-52. PubMed ID: 31229261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand.
    Sirinawasatien A; Techasirioangkun T
    PLoS One; 2020; 15(2):e0229517. PubMed ID: 32106270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
    Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
    J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sofosbuvir-containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment.
    Eletreby R; El-Serafy M; Anees M; Kasem G; Salama M; Elkhouly R; Hamdy M; Abdel Haleem H; Kamal E; Abdel-Razek W; Salama R; Elshenawy M; Shafeek A; Hassany M; El-Sayed MH; El-Shazly Y; Esmat G
    Liver Int; 2020 Apr; 40(4):797-805. PubMed ID: 31858694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment.
    Liu CH; Chen CY; Su WW; Tseng KC; Lo CC; Liu CJ; Chen JJ; Peng CY; Shih YL; Yang SS; Huang CS; Huang KJ; Chang CY; Tsai MC; Kao WY; Fang YJ; Chen PY; Su PY; Tseng CW; Huang JJ; Lee PL; Lai HC; Hsieh TY; Chang CH; Huang YJ; Lee FJ; Chang CC; Kao JH
    Gut; 2022 Jan; 71(1):176-184. PubMed ID: 33408122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study.
    Lawitz E; Landis CS; Flamm SL; Bonacini M; Ortiz-Lasanta G; Huang J; Zhang J; Kirby BJ; De-Oertel S; Hyland RH; Osinusi AO; Brainard DM; Robson R; Maliakkal BJ; Gordon SC; Gane EJ
    Lancet Gastroenterol Hepatol; 2020 Oct; 5(10):918-926. PubMed ID: 32531259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.